Phase lll Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors (Intergroup)
Publication Information Expand/Collapse
PMid: PMID29370458 | PMC number: PMC5963502
PMid: PMID27986655 | PMC number: PMC5370550
PMid: PMID28586789; PMC5710507
Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814
Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – transcriptome expression analysis of the phase III trial SWOG-8814
Association between BMI at treatment initiation and cancer survival across multiple SWOG trials
PMid: PMID22152853 | PMC number: PMC3273723
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [PMID20005174; PMC3058239]
Potential tumor biologic causes of the racial survival disparity in ER-positive breast cancer adjuvant trials
In the interest of full disclosure - author's reply [correspondence] [PMID20359663]
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node positive breast cancer: a phase 3 open-label, randomised controlled trial [PMID20004966; PMC3140679]
Treatment quality and outcomes of African American versus Caucasian breast cancer patients: retrospective analysis of Southwest Oncology Group studies S8814-S8897 [PMC2674002; PMID19307504]
Prediction of 10-year chemotherapy benefit and breast cancer-specific survival by the 21-gene recurrence score (RS) assay in node-positive, ER-positive breast cancer - An update of SWOG-8814 (INT0100)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-negative, ER-positive breast cancer (S8814, INT0100)
Outcome of African American women with breast cancer in cooperative group clinical trials
Treatment quality and outcome of African American vs. European American breast cancer patients: retrospective analysis of southwest oncology group studies S8814/S8897
Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814)
Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup trial 0100 (SWOG-8814).
Overall survival after cyclophosphamide, adriamycin, 5-Fu, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor (+), node (+) breast cancer: new findings from phase III Southwest Oncology Group Intergroup trial S8814 (INT-0100)
Tamoxifen (T) versus cyclophosphamide, adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100).
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup studies.
The influence of patient characteristics, socioeconomic (SES) factors, geography, and systemic risk on the use of breast sparing treatment in adjvant breast cancer studies.